Saquinavir/Low-dose Ritonavir: its Use in HIV Infection

Saquinavir/Low-dose Ritonavir: its Use in HIV Infection

Margaret Johnson 1, Barry Peters 1

1 NULL

*Correspondence: Barry Peters, Email not available

Abstract

Exposure to saquinavir can be increased considerably by pharmacokinetic enhancement with ritonavir, without having a substantial impact on tolerability. Clinical trials indicate that both once-daily and twice-daily saquinavir/ritonavir treatment regimens, generally at dosages of 1,600 mg/100 mg once daily and 1,000 mg/100 mg twice daily, provide potent and sustained viral suppression and are well tolerated. In addition, data suggest that “double-boostingâ€? strategies, including the combination of saquinavir with lopinavir/ritonavir, provide valuable treatment options in the salvage setting.

Keywords: Pharmacokinetics. Ritonavir. Saquinavir. HIV infection. Boosted.

Contents

DOI not available
Add to Mendeley
    Descargar PDF
    English versión
    DOI not available